Featured Image
February 8 – 2023

Anker Lundemose is appointed chairman of the board

Commit welcomes Anker Lundemose as executive chairman of the board. MD, PhD Anker Lundemose is CEO at Mission Therapeutics (backed by Sofinnova Partners, Roche Venture Fund, Pfizer Ventures and SR One) and has held numerous management and board positions in high-profile biotech companies. With extensive experience in business development, corporate development, M&A strategy and execution, financing as well as R&D, Anker will help set the direction and shape the future of Commit biologics.

More news

© 2022 Commit Biologics. All rights reserved.